½ñÄê»á¹ÙÍø

EN
½ñÄê»á | ¹Ù·½ÍøÕ¾
Chronic Disease Drug Innovation Platform

Âý²¡Ò©Á¢ÒìÆ½Ì¨

¾ß±¸ÁËÁ¢ÒìÒ©ÖØÐÂÑз¢£¬£¬£¬£¬ £¬£¬£¬£¬ÒÔ¼°¸ß¶Ë¿Ú·þ»º¿ØÊÍÖÆ¼ÁµÄÑб¬·¢²úÄÜÁ¦

¶à¸öÁ¢ÒìÒ©Î↑չȫÇòÁÙ´²ÊÔÑé

 


· ½¨ÓÐÂý²¡Á¢ÒìÒ©ÊÖÒÕÖÐÐÄ¡¢¿Ú·þ»º¿ØÊÍÖÆ¼ÁÑо¿ÊµÑéÊÒºÍÉú²úÊÖÒÕת»¯ÖÐÐÄ£¬£¬£¬£¬ £¬£¬£¬£¬¾ß±¸Á¢ÒìÒ©È«Á÷³Ì¼°¶àÖÖÊÖÒÕÀàÐ͸߶˿ڷþ»º¿ØÊÍÖÆ¼ÁµÄ×ÔÖ÷Ñз¢¼°Éú²úÄÜÁ¦¡£ ¡£¡£¡£¡£¡£¡£

 

· Óë¹ãÖÝʵÑéÊÒ¹²½¨Á¢ÒìÒ©ÊÖÒÕ¹¤Òµ×ª»¯ÖÐÐÄ£¬£¬£¬£¬ £¬£¬£¬£¬¼ÓËÙÁ¢ÒìÒ©Ñб¬·¢²ú£¬£¬£¬£¬ £¬£¬£¬£¬Ôö½øÁ¢ÒìÒ©¹¤ÒµµÄÉú³¤£¬£¬£¬£¬ £¬£¬£¬£¬ÊµÏÖ¿ÆÑÐÏîĿЧ¹ûת»¯¡£ ¡£¡£¡£¡£¡£¡£

 

  • ½ñÄê»á | ¹Ù·½ÍøÕ¾
    ½¹µãÓÅÊÆ
      • Òѽ¨ÉèÂý²¡Á¢ÒìÒ©ÊÖÒÕÖÐÐÄ¡¢¿Ú·þ»º¿ØÊÍÖÆ¼ÁÑо¿ÊµÑéÊÒºÍÉú²úÊÖÒÕת»¯ÖÐÐÄ

      • ¾ß±¸Á¢ÒìÒ©È«Á÷³Ì¼°¶àÖÖÊÖÒÕÀàÐ͸߶˿ڷþ»º¿ØÊÍÖÆ¼ÁµÄ×ÔÖ÷Ñз¢¼°Éú²úÄÜÁ¦

      • Óë¹ãÖÝʵÑéÊÒ¹²½¨Á¢ÒìÒ©ÊÖÒÕ¹¤Òµ×ª»¯ÖÐÐÄ£¬£¬£¬£¬ £¬£¬£¬£¬¼ÓËÙÁ¢ÒìÒ©Ñб¬·¢²ú£¬£¬£¬£¬ £¬£¬£¬£¬Ôö½øÁ¢ÒìÒ©¹¤ÒµµÄÉú³¤£¬£¬£¬£¬ £¬£¬£¬£¬ÊµÏÖ¿ÆÑÐÏîĿЧ¹ûת»¯

      rewrweer
  • ½ñÄê»á | ¹Ù·½ÍøÕ¾
    ²úÆ·¹ÜÏß
      • ÒÑÓÐ67¸öÂý²¡Ò©×¢²áÅú¼þ

      • º­¸ÇÐÄÄÔѪ¹Ü¼²²¡¡¢ÉöÔ༲²¡¡¢Ïû»¯ÏµÍ³¼²²¡¡¢¸Î²¡µÈ¼²²¡ÖÎÁÆÁìÓò

      rewrweer
  • ½ñÄê»á | ¹Ù·½ÍøÕ¾
    ÔÚÑйÜÏß
      • ÔÚÑÐÂý²¡Ò©°üÀ¨È«ÇòÁ¢ÒìÒ©AR882µÈÏîÄ¿29¸ö

      • ¾ù¾ßÓжÀ¼ÒרÀûºÍÆæÒìÖÎÁÆÓÅÊÆ

      • ÔÚÑÐÍ´·çÁ¢ÒìÎïAR882Ч¹ûÓÅÓÚÁÙ´²Ò»ÏßÒ©Î£¬£¬£¬ £¬£¬£¬£¬¾ßÓÐÈ«Çò¾ºÕùÓÅÊÆ

      rewrweer
  • ½ñÄê»á | ¹Ù·½ÍøÕ¾
    ÓÅÒìЧ¹û
      • AR882ÒÑÍê³ÉµÄÈ«Çò¶àÖÐÐÄ¢òBÆÚÁÙ´²ÊÔÑéÊý¾ÝÏÔʾ£ºAR882ÁÆÐ§¸üÏÔÖø£¬£¬£¬£¬ £¬£¬£¬£¬Çå¾²ÐÔ¸ü¸ß£¬£¬£¬£¬ £¬£¬£¬£¬¾ßÓгÉΪFirst-in-class ¼° Best-in-classÓÅÊÆ²úƷDZÁ¦£¬£¬£¬£¬ £¬£¬£¬£¬ÒÑ»ñµÃÃÀ¹úFDAÊÚÓèµÄ¿ìËÙͨµÀ×ʸñ£¨FTD£©

      • ¶à¸ö²úÆ·ÈëÑ¡¡¶¹ú¼Ò»ù±¾Ò©ÎïĿ¼¡·ºÍ¡¶¹ú¼ÒÒ½±£Ä¿Â¼¡·

      rewrweer

È«ÇòÁ¢ÒìÒ©AR882Ñз¢½ø¶È

½ñÄê»á | ¹Ù·½ÍøÕ¾

Âý²¡Ò©Ñз¢¹ÜÏß

½ñÄê»á | ¹Ù·½ÍøÕ¾

½ñÄê»á | ¹Ù·½ÍøÕ¾

 

ÍøÕ¾µØÍ¼